The largest increases in product liability filings involving pharmaceuticals last month were seen in claims against Bayer and Janssen Pharmaceuticals’ blood thinner Xarelto, and Fresenius Medical Care’s dialysis concentrates GranuFlo and NaturaLyte, according to Reuters’ analysis of statistics from the U.S. Judicial Panel on Multidistrict Litigation. Bayer and Janssen, a subsidiary of Johnson & Johnson, have enjoyed billion-dollar profits from their blood thinner Xarelto since it hit the market in 2011. Xarelto has since been approved for multiple indications including stroke prevention in patients with nonvalvular atrial fibrillation, treating and preventing blood clots in the legs and lungs, and preventing blood ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.